The novel anti-CD19 autologous CAR T-cell therapy obecabtagene autoleucel achieved durable remissions in 40% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia without a subsequent stem cell transplant, according to results from the phase Ib/II FELIX clinical trial presented by Elias Jabbour, professor of leukemia at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.
If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.
